Exact Mass: 463.3005836

Exact Mass Matches: 463.3005836

Found 51 metabolites which its exact mass value is equals to given mass value 463.3005836, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Gentamicin C2

Gentamicin C2 Pentaacetate Salt

C20H41N5O7 (463.30058360000004)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

   

Sagamicin

2-[4,6-Diamino-3-[3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.3005836)


Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

gentamicin C2a

gentamicin C2a

C20H41N5O7 (463.30058360000004)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins

   

LysoPE(P-18:1(9Z)/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-[(1Z,9Z)-octadeca-1,9-dien-1-yloxy]propoxy]phosphinic acid

C23H46NO6P (463.30625860000004)


LysoPE(P-18:1(9Z)/0:0) is a phospho-ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin and choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

   

Gentamicin C2

2-[(4,6-diamino-3-{[3-amino-6-(1-aminoethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl)oxy]-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.30058360000004)


   

Micronomicin

2-{[4,6-diamino-3-({3-amino-6-[(methylamino)methyl]oxan-2-yl}oxy)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.30058360000004)


   

Peregrine

11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

C26H41NO6 (463.29337260000005)


   
   

Phosphatidylethanolamine lyso alkenyl 18:1

Phosphatidylethanolamine lyso alkenyl 18:1

C23H46NO6P (463.30625860000004)


   
   

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

"((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine"

C26H41NO6 (463.29337260000005)


   

AQ-RA 741

11-[[4-[4-(Diethylamino)butyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-B][1,4]benzodiazepin-6-one

C27H37N5O2 (463.2947102)


   
   

(1R,2S,3R,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-ribo-heptopyranoside

(1R,2S,3R,4R,6S)-4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyloxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-ribo-heptopyranoside

C20H41N5O7 (463.30058360000004)


   

N-[(3alpha,5beta,12alpha)-3,12-dihydroxy-7,24-dioxocholan-24-yl]glycine

N-[(3alpha,5beta,12alpha)-3,12-dihydroxy-7,24-dioxocholan-24-yl]glycine

C26H41NO6 (463.29337260000005)


   

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pent-2-enoyl)glycine

C26H41NO6 (463.29337260000005)


   

2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate

2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] hydrogen phosphate

C23H46NO6P (463.30625860000004)


   

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dec-4-ene-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]undecane-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]decane-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)undec-4-ene-1-sulfonic acid

C23H45NO6S (463.29674300000005)


   

cis-5-(6-Carboxyhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

cis-5-(6-Carboxyhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

C30H41NO3 (463.3086276)


   

(3S)-5beta-(6-Formylhexyl)-4alpha-[(E)-3-hydroxy-1-octenyl]-2,3alpha-diphenylisoxazolidine

(3S)-5beta-(6-Formylhexyl)-4alpha-[(E)-3-hydroxy-1-octenyl]-2,3alpha-diphenylisoxazolidine

C30H41NO3 (463.3086276)


   
   

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

2-[[(4E,8E)-2-acetamido-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(4E,8E)-2-acetamido-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C22H44N2O6P+ (463.2936834)


   

Micronomicin

(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

C20H41N5O7 (463.3005836)


Micronomicin is an antibiotic that belongs to the aminoglycoside class of organic compounds. Aminoglycosides are characterized by aminocyclitols linked to amino sugars, forming aminoglycoside antibiotics. These compounds are known for their broad-spectrum activity against various microorganisms, particularly bacteria. Micronomicin, specifically, features a structure where an aminocyclitol is connected to an amino sugar through a glycosidic bond. This structure is typical of aminoglycosides and contributes to their antimicrobial properties. The exact configuration and arrangement of atoms in micronomicin give it its specific antimicrobial profile. Micronomicin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=52093-21-7 (retrieved 2024-10-09) (CAS RN: 52093-21-7). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

lysophosphatidylethanolamine P-18:1

lysophosphatidylethanolamine P-18:1

C23H46NO6P (463.30625860000004)


A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group contains 18 carbons and has 1 additional double bond

   

NA-Dopamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Dopamine 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C30H41NO3 (463.3086276)


   
   
   
   

NMI 8739

NMI 8739

C30H41NO3 (463.3086276)


NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine.

   

(1s,12r,14r,15r,16s,17s,20s)-14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

(1s,12r,14r,15r,16s,17s,20s)-14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

C30H41NO3 (463.3086276)


   

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,16s,17r,18r)-11-ethyl-4-hydroxy-6,8,16-trimethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-18-yl acetate

C26H41NO6 (463.29337260000005)


   

14-acetyltalatizamine

NA

C26H41NO6 (463.29337260000005)


{"Ingredient_id": "HBIN001359","Ingredient_name": "14-acetyltalatizamine","Alias": "NA","Ingredient_formula": "C26H41NO6","Ingredient_Smile": "NA","Ingredient_weight": "463.61","OB_score": "NA","CAS_id": "71239-55-9","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9321","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16r,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16r,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C26H41NO6 (463.29337260000005)


   

11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C26H41NO6 (463.29337260000005)


   

(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

(1s,2r,3r,4r,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C26H41NO6 (463.29337260000005)


   

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-4-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

(1s,2r,3r,4s,5s,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-4-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

C26H41NO6 (463.29337260000005)


   

(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

(1s,2r,3r,4s,5r,6s,8s,9s,10r,13s,16s,17r)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C26H41NO6 (463.29337260000005)


   

(1r,2s,3s,4s,5s,6r,8r,9r,10s,13r,16r,17s)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

(1r,2s,3s,4s,5s,6r,8r,9r,10s,13r,16r,17s)-11-ethyl-8-hydroxy-6,16-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl acetate

C26H41NO6 (463.29337260000005)


   

14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

14-hydroxy-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

C30H41NO3 (463.3086276)